Fig. 2From: Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective studyKaplan–Meier survival curve for PFS(left) and OS(right) for patients with no residual tumor in the NACT group (NACT-R0) based on chemosensitivity, patients with residual tumor less than 1 cm in the PDS-R1 subgroup and with residual tumor larger than 1 cm in the PDS-R2 subgroupBack to article page